Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...425426427428429430431432433434435...10671068»
  • ||||||||||  dexamethasone / Generic mfg., cisplatin / Generic mfg.
    Clinical, Journal, Head-to-Head:  Dexamethasone-sparing regimens with oral NEPA for the prevention of emesis caused by high-dose cisplatin: A randomized non-inferiority study. (Pubmed Central) -  Oct 27, 2021   
    Our study demonstrates, for the first time, comparable antiemetic control during the 5-days post-chemotherapy with a simplified three-drug regimen of NEPA (netupitant/palonosetron) plus single-dose DEX versus the standard 4-day DEX reference treatment in patients undergoing high-dose cisplatin. This represents a clinically relevant achievement as it not only simplifies antiemetic prophylaxis but also offers an opportunity to minimize DEX-related side effects and appropriately use in patients where caution with corticosteroid use is advised.
  • ||||||||||  budesonide / Generic mfg.
    Clinical, Review, Journal:  Glucocorticoid Therapy in Inflammatory Bowel Disease: Mechanisms and Clinical Practice. (Pubmed Central) -  Oct 27, 2021   
    Topical administration of a second-generation of GCs, such as budesonide and beclomethasone dipropionate (BDP), represents a valid alternative to use of older, systemic GCs...One approach is to consider new GC mediators, such as glucocorticoid-induced leucine zipper, which may have similar anti-inflammatory properties, but avoids the side effects of GCs. This in-depth analysis can help to improve the development and the clinical outcomes of GC therapies in IBD.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Salvianolic Acid A Suppresses DNCB-Induced Atopic Dermatitis-Like Symptoms in BALB/c Mice. (Pubmed Central) -  Oct 27, 2021   
    After induction of atopic dermatitis, salvianolic acid A (5 and 10 mg/kg) or dexamethasone (10 mg/kg) were administrated via intraperitoneal injection for 3 weeks...Furthermore, salvianolic acid A blocked DNCB-induced lymph node enlargement. In summary, these results suggest that salvianolic acid A might have a therapeutic potential for the treatment of AD.
  • ||||||||||  budesonide / Generic mfg.
    Journal:  Hot punching for loading of biodegradable microcontainers with budesonide-Soluplus film. (Pubmed Central) -  Oct 27, 2021   
    Solid-state characterization indicates that the drug is in an amorphous state in the drug-polymer films and the in vitro drug release profile showed a 68% release over 10 h. The results demonstrate that hot punching can be employed both as a production and loading method for PCL microcontainers with the perspective of local treatment of IBD.
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg.
    Biomarker, Clinical, Retrospective data, Journal:  Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome. (Pubmed Central) -  Oct 27, 2021   
    Two patients developed grade-1 bortezomib-induced peripheral neuropathy and were reversible after drug withdrawal. After a median follow-up of 22.5 months, the estimated 2-year overall survival and time to next treatment were 95.7% and 65.6%, respectively. In conclusion, the combination of bortezomib and dexamethasone is effective, with a high response rate and safety profile for patients with newly diagnosed POEMS syndrome.
  • ||||||||||  cisplatin / Generic mfg.
    Clinical, Journal:  Symmetrical Skin Lesions on the Gluteal Region in a Patient with Anti-Laminin-332 Mucous Membrane Pemphigoid. (Pubmed Central) -  Oct 27, 2021   
    Although the gastric cancer and liver metastasis initially responded to chemotherapy with fluorouracil and cisplatin, the patient succumbed to multiple organ failure 9 months after the initial visit...MMP primarily affects the mucous membranes, and widespread skin lesions are rare. Our case emphasizes that clinicians need to specifically check for the presence of skin lesions on weight-bearing parts of the body during examination of patients with suspected MMP.
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
    Clinical, Journal:  Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar. (Pubmed Central) -  Oct 27, 2021   
    The treatment of HS includes topical clindamycin, triamcinolone acetonide, clobetasol, topical resorcinol, oral antibiotics, hormonal therapy, oral retinoids, and biologic therapies (11)...The patient was treated with betadine solution and pus drainage until 2018, when at the Department of Dermatology and Venerology prescribed adalimumab in doses of 80 mg initially, 40 mg ×2 on the first day and the day after that, then 80 mg after fifteen days followed by 40 mg every ten days...Adalimumab, infliximab, and etanercept have all been tested in the treatment of hidradenitis suppurativa but vary in effectiveness and in how well they have been studied...Therapeutic options for hidradenitis suppurativa were long restricted to the use of local disinfectants and systemic antibiotics as well as repeated incisions and drainage, which produce only short-term benefits. Our patients showed regression of lesions after sixteen weeks of biological therapy.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Chemoproteomic profiling reveals cellular targets of nitro-fatty acids. (Pubmed Central) -  Oct 27, 2021   
    Bioinformatic analyses revealed that nitro-alkylated proteins are highly enriched in endoplasmic reticulum and transmembrane proteins, and are overrepresented in lipid metabolism and transport pathways. This study significantly expands the scope of protein substrates targeted by nitro-fatty acids in living cells and provides a useful resource towards understanding the pleiotropic biological roles of nitro-fatty acids as signaling molecules or as multi-target therapeutic agents.
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Trial completion date, Trial primary completion date:  Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis (clinicaltrials.gov) -  Oct 26, 2021   
    P2,  N=24, Recruiting, 
    Furthermore, by investigating multiple risk factors that could be related to inter-patient variability in developing these side effects, we might be able to identify and treat patients who are at risk earlier during treatment. Trial completion date: May 2021 --> Sep 2022 | Trial primary completion date: Feb 2021 --> Sep 2022
  • ||||||||||  dexamethasone / Generic mfg., dexmedetomidine / Generic mfg.
    Trial suspension, Trial primary completion date:  AADDCToR: Adjuncts for Adductor Block: Dexamethasone,Dexmedetomidine, or Combination to Reduce Pain (clinicaltrials.gov) -  Oct 26, 2021   
    P4,  N=252, Suspended, 
    Active, not recruiting --> Completed | Trial completion date: Apr 2022 --> Oct 2021 Recruiting --> Suspended | Trial primary completion date: Sep 2022 --> Dec 2022
  • ||||||||||  hydroxychloroquine / Generic mfg., dexamethasone / Generic mfg., sirolimus / Generic mfg.
    Trial completion date, Trial primary completion date, Combination therapy:  COVID19-HOPE: Hydroxychloroquine in Combination With Sirolimus and Dexamethasone for Treating COVID-19 Patients (clinicaltrials.gov) -  Oct 26, 2021   
    P=N/A,  N=58, Not yet recruiting, 
    Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2022 --> Jun 2023 Trial completion date: Sep 2020 --> Sep 2022 | Trial primary completion date: Aug 2020 --> Aug 2022
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Potent Anti-Inflammatory, Arylpyrazole-Based Glucocorticoid Receptor Agonists That Do Not Impair Insulin Secretion. (Pubmed Central) -  Oct 25, 2021   
    Activity observed in compounds bearing an electron deficient arylpyrazole moiety showed promise toward a dissociated steroid, displaying transrepression while having limited transactivation activity. In addition, compounds 11aa and 11ab were found to have anti-inflammatory efficacy comparable to that of dexamethasone at 10 nM, with minimal transactivation activity and no reduction of insulin secretion in cultured rat 832/13 beta cells.
  • ||||||||||  dexamethasone / Generic mfg.
    Clinical, Journal:  Predictors for time to awake in patients undergoing awake craniotomies. (Pubmed Central) -  Oct 25, 2021   
    While most patients undergoing awake craniotomy are awake within a reasonable time frame after discontinuation of propofol and remifentanil infusion, time to awake exceeded 20 minutes in 17% of the patients. Increasing age, nonsmoker status, and higher ASA classification were found to be associated with a prolonged time to awake.
  • ||||||||||  Revlimid (lenalidomide) / BMS, Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Journal:  Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils. (Pubmed Central) -  Oct 25, 2021   
    Similarly, in NDMM patients, lenalidomide but not bortezomib upregulated FcγRI/CD64 expression, improving phagocytic activity and oxidative bursta as tested in vitro. Conclusions Our combined biological and clinical data provide new information on the ability of pomalidomide and lenalidomide to modulate the functional activity of neutrophils, despite their chronic activation due to FcγRI/CD64 overexpression.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty
    Enrollment closed, Trial completion date, Trial primary completion date:  Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease (clinicaltrials.gov) -  Oct 25, 2021   
    P2,  N=84, Active, not recruiting, 
    Based on these results, it is reasonable to speculate that a surgery-dependent plan for the prevention of POV is feasible for patients in similar clinical settings. Recruiting --> Active, not recruiting | Trial completion date: Apr 2022 --> Nov 2021 | Trial primary completion date: Apr 2022 --> Nov 2021